WHO Issues Concern Over Acute Lack of Weight-Loss Jabs
Under one in 10 people eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it releases its first guidance on the drugs.
Given more than one billion people worldwide now living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
Per estimates, over two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that obesity is a chronic disease that can be addressed with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the treatments that can aid individuals in losing considerable body mass, notes the agency.
Skinny Jab Scarcity
Even under the present best projected scenario, the supply of these medications would only suffice for approximately 100 million people – less than 10% of the global need, as stated by the WHO.
The advice encourages countries and companies to widen access, by approaches like voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Injections Work
The injections mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals eat less.
Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Evidence indicates patients may see weight return a year later of halting the medication, as their typical food cravings resume.
Being overweight or obese increases your chance for contracting health problems, such as diabetes, heart disease, brain attack, and certain malignancies.
Excess weight affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
